Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock

Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, Inc. (NASDAQ:ELVN), sold 5,000 shares of the company’s common stock on October 19, 2026. The sale generated a total value of $192,342, with shares trading at prices ranging from $37.785 to $38.75. The weighted average sale price for these transactions was $38.4684 per share. The stock has since risen to $41.82, reflecting a remarkable year-to-date return of 172% for the biotechnology company with a market capitalization of $3.09 billion.

On the same day, Ms. Collins also acquired 5,000 shares of Enliven Therapeutics common stock through the exercise of stock options. These shares were acquired at an exercise price of $2.48 per share, totaling $12,400. All shares subject to this option were fully vested and exercisable.

Both the option exercise and the subsequent sale were executed under a Rule 10b5-1 trading plan, which Ms. Collins adopted on October 19, 2025.

Following these transactions, Ms. Collins directly holds 25,000 shares of Enliven Therapeutics common stock. Additionally, she holds 101,268 stock options. Some of the securities held are Restricted Stock Units (RSUs), which represent a contingent right to receive one share of the Issuer’s Common Stock, subject to their respective vesting schedules and conditions. According to InvestingPro analysis, ELVN currently appears overvalued relative to its Fair Value, though the company maintains a strong balance sheet with more cash than debt.

In other recent news, Enliven Therapeutics has made significant strides in its clinical trials and received attention from multiple analyst firms. The company announced its alignment with the FDA regarding the design of its planned Phase 3 ENABLE-2 trial, which will evaluate relcobatinib (ELVN-001) in chronic myeloid leukemia patients. This development has led to H.C. Wainwright raising its price target for the company to $73 while maintaining a Buy rating. Similarly, Guggenheim reiterated its Buy rating with a price target of $78, citing the FDA alignment as a key factor.

Morgan Stanley initiated coverage on Enliven Therapeutics with an Overweight rating and a $70 price target, highlighting the company’s focus on precision oncology. JPMorgan also started coverage with an Overweight rating, setting a price target of $75, emphasizing the potential of ELVN-001 in treating chronic-phase CML. William Blair initiated coverage with an outperform rating, noting the expanding market for chronic myeloid leukemia treatments. These recent developments reflect growing interest and optimism from analysts regarding Enliven Therapeutics’ future prospects in the oncology sector.